

# Martin T King

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4357706/publications.pdf>

Version: 2024-02-01

56  
papers

413  
citations

759233

12  
h-index

839539

18  
g-index

56  
all docs

56  
docs citations

56  
times ranked

661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	3.1	40
2	Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2019, 154, 595-601.	1.4	35
3	Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 75-82.	0.8	34
4	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. <i>Brachytherapy</i> , 2021, 20, 1114-1129.	0.5	26
5	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 973-978.	0.4	24
6	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017, 123, 4832-4840.	4.1	20
7	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019, 18, 186-191.	0.5	18
8	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
9	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1279-1285.	0.8	18
10	Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. <i>Cancer</i> , 2018, 124, 3528-3535.	4.1	15
11	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 953-959.	1.3	14
12	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 226-234.	1.9	14
13	Race- and Age-Related Disparities in Cervical Cancer Mortality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 789-795.	4.9	11
14	Simulation-based graduate medical education in MR-guided brachytherapy for cervical cancer. <i>Brachytherapy</i> , 2020, 19, 725-731.	0.5	11
15	Vaginal recurrence of endometrial cancer: MRI characteristics and correlation with patient outcome after salvage radiation therapy. <i>Abdominal Radiology</i> , 2020, 45, 1122-1131.	2.1	10
16	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.8	9
17	Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 53-58.	0.8	9
18	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 414-422.	3.9	9

#	ARTICLE	IF	CITATIONS
19	Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. <i>Journal of Urology</i> , 2020, 203, 115-119.	0.4	9
20	Salvage radiation therapy for localized recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 916-921.	2.5	8
21	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021, 161, 241-250.	0.6	7
22	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	1.6	6
23	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 904-911.	0.8	6
24	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 157.e15-157.e20.	1.6	6
25	ACRâ€“ABSâ€“ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 1071-1082.	0.5	5
26	Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111092.	5.9	4
27	Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, 95-103.	2.1	3
28	MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 163, 453-458.	1.4	3
29	First pointwise encoding time reduction with radial acquisition (PETRA) implementation for catheter detection in interstitial high-dose-rate (HDR) brachytherapy. <i>Brachytherapy</i> , 2022, 21, 501-510.	0.5	3
30	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e9-735.e15.	1.6	2
31	Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1908-1914.	2.5	2
32	Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13394.	1.2	2
33	Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002536.	2.5	2
34	Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. <i>Brachytherapy</i> , 2019, 18, 198-203.	0.5	1
35	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020, 145, 197-203.	1.0	1
36	Selection criteria for high-dose-rate surface brachytherapy and electron beam therapy in cutaneous oncology. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 195-204.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes of magnetic resonance image-guided partial prostate brachytherapy for favorable-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 138-138.	1.6	1
38	External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.. Journal of Clinical Oncology, 2019, 37, 21-21.	1.6	1
39	Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer.. Journal of Clinical Oncology, 2020, 38, 135-135.	1.6	1
40	INTREPId (INTERmediate Risk Erektion Preservation Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS384-TPS384.	1.6	1
41	Interfraction dose deviation and catheter position in cervical interstitial and intracavitary image guided HDR brachytherapy. Medical Dosimetry, 2021, . .	0.9	1
42	Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.. Journal of Clinical Oncology, 2020, 38, 101-101.	1.6	1
43	ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 249-257.	1.3	1
44	A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. Current Problems in Cancer, 2019, 43, 443-449.	2.0	0
45	Reply to Partial gland therapy for prostate cancer. Cancer, 2019, 125, 819-820.	4.1	0
46	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy, 2021, 20, 1-9.	0.5	0
47	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.. Journal of Clinical Oncology, 2021, 39, 205-205.	1.6	0
48	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Journal of Clinical Oncology, 2021, 39, 121-121.	1.6	0
49	Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer. Practical Radiation Oncology, 2021, 11, 394-403.	2.1	0
50	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 50-50.	1.6	0
51	Practice patterns and outcomes among patients with NOMO prostate cancer and a very high prostate-specific antigen.. Journal of Clinical Oncology, 2018, 36, 48-48.	1.6	0
52	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 78-78.	1.6	0
53	Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. Journal of Clinical Oncology, 2018, 36, 23-23.	1.6	0
54	Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 5588-5588.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Practice Patterns and Outcomes Among Patients With NOMO Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 941-948.	4.9	0
56	Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancer. <i>Brachytherapy</i> , 2022, , .	0.5	0